Experimental Unapproved Treatments for COVID-19

DBCAT005151Pharmacologic class

Drugs that are being investigated as potential treatment options for coronavirus disease 2019 (COVID-19). Towards the end of 2019, a large number of patients in Wuhan, China presented with atypical pneumonia. A DrugBank category of 115 drugs. 27 of them are approved.

Also known as: COVID-19: Prevention & Investigational Treatments · Investigational treatments for COVID-19 · Potential treatments for Coronavirus Disease (COVID-19) · Potential treatments for COVID-19
Drugs: Abdavomeran
Abivertinib
Acetylcysteine zidrimer
Ad5-nCoV
Alunacedase alfa
Amubarvimab
Anti-SARS-CoV-2 REGN-COV2
APL-9
AstraZeneca COVID-19 Vaccine
AT-301
AZD7442
Azithromycin
Azvudine
Bamlanivimab
Baricitinib
BCc1
Beta-(1,3)-D glucan
beta-Hydroxybutyric acid
Bevacizumab
Bexotegrast
BNT162a1 SARS-CoV-2 Vaccine
BNT162c2 SARS-CoV-2 Vaccine
Carrimycin
Chloroquine
CIGB 300
and 90 more with a free account

What you can answer from here — as of May 26, 2021

115DrugsEach linked to its full drug card

451Drug targetsEvery drug–target pair in the class, with bond type

12,174Marketed productsAcross the regions we cover, with dosage forms and routes

37Routes of administrationHow the drugs in this class are given

Which targets do Experimental Unapproved Treatments for COVID-19 share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account